Skip to Main Content

Paper Details

Ferrous iron-activatable drug conjugate achieves potent MAPK blockade in KRAS-driven tumors.
J Exp Med
15
2022
Fe2+, FeADCs, Ferrous iron, KRAS, KRAS mutations, KRAS-driven tumors, MAPK, MEK, RAF, RAS, cancer, ferrous iron, mutant KRAS, normal, oncogenic KRAS, solid tumors, tumor, tumor cell, tumor cells
Author NameAffiliation
Adam B OlshenHelen Diller Family Comprehensive Cancer Center, University of California san francisco
Adam B OlshenUniversity of California san francisco
Spencer C BehrUniversity of California san francisco
James E KorkolaCenter for Spatial Systems Biomedicine, Oregon Health & Sciences University
Eric A CollissonUniversity of California san francisco
Eric A CollissonHelen Diller Family Comprehensive Cancer Center, University of California san francisco
Adam R RensloHelen Diller Family Comprehensive Cancer Center, University of California san francisco
Adam R RensloDepartment of Pharmaceutical Chemistry, University of California san francisco
  • 1 - 8

Datasets

Release 1.2